公开(公告)号：US20230142839A1

公开(公告)日：2023-05-11

申请号：US17940902

申请日：2022-09-08

Applicant: Array BioPharma Inc.

Inventor： Joseph P. LYSSIKATOS ,  Julie Marie HICKS ,  Fredrik P. MARMSATER ,  Qian ZHAO

IPC: A61K31/337 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D519/00 ,  C07D471/04 ,  A61K31/513 ,  A61K31/517 ,  A61K39/395

CPC classification number: A61K31/337 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D519/00 ,  C07D471/04 ,  A61K31/513 ,  A61K31/517 ,  A61K39/3955

Abstract: This invention provides compounds of Formula I




wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

公开(公告)号：US11634417B2

公开(公告)日：2023-04-25

申请号：US16835702

申请日：2020-03-31

Applicant: Array BioPharma Inc.

Inventor： James F. Blake ,  Mark Laurence Boys ,  Mark Joseph Chicarelli ,  Adam W. Cook ,  Mohamed S. A. Elsayed ,  Jay Bradford Fell ,  John P. Fischer ,  Ronald Jay Hinklin ,  Yutong Jiang ,  Oren T. McNulty ,  Macedonio J. Mejia ,  Martha E. Rodriguez ,  Christina E. Wong

IPC: C07D253/06 ,  A61K31/53 ,  C07D471/04 ,  A61P35/00 ,  C07D401/14 ,  C07D471/10 ,  C07D513/10 ,  A61K45/06

Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：US20230077225A1

公开(公告)日：2023-03-09

申请号：US17869575

申请日：2022-07-20

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Xiaolun Wang ,  Aaron Craig Burns ,  James Gail Christensen ,  John Michael Ketcham ,  John David Lawson ,  Matthew Arnold Marx ,  Christopher Ronald Smith ,  Shelley Allen ,  James F. Blake ,  Mark Joseph Chicarelli ,  Joshua Ryan Dahlke ,  Donghua Dai ,  Jay Bradford Fell ,  John Peter Fischer ,  Macedonio J. Mejia ,  Brad Newhouse ,  Phong Nguyen ,  Jacob Matthew O'Leary ,  Spencer Pajk ,  Martha E. Rodriguez ,  Pavel Savechenkov ,  Tony P. Tang ,  Guy P.A. Vigers ,  Qian Zhao ,  Dean Russell Kahn ,  John Gaudino ,  Michael Christopher Hilton

IPC: C07D519/00

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20230041385A1

公开(公告)日：2023-02-09

申请号：US17849621

申请日：2022-06-25

Applicant: Array BioPharma Inc.

Inventor： Bryan Daniel ELLIS ,  Erik James HICKEN ,  Ellen Ruth LAIRD ,  Nicholas Charles LAZZARA ,  Bradley Jon NEWHOUSE ,  Spencer Phillip PAJK ,  Rachel Zoe Rosen ,  Russell Andrew Shelp

IPC: A61K31/519 ,  C07D519/00 ,  C07D471/04 ,  A61K31/551 ,  A61K31/55 ,  A61K31/5386 ,  A61K39/395 ,  A61K31/704 ,  A61K31/337 ,  A61K38/14 ,  A61K31/506 ,  A61K31/502 ,  A61K31/655 ,  A61K31/573 ,  A61K31/7048 ,  A61K31/44

Abstract: This invention relates to compounds of Formula (I): and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein A, L2, R1, R2, R3, R4, and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts, and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20220289721A1

公开(公告)日：2022-09-15

申请号：US17745346

申请日：2022-05-16

Applicant: Array BioPharma Inc.

Inventor： Patrick Michael BARBOUR ,  Katie Keaton BROWN ,  Adam Wade COOK ,  Erik James HICKEN ,  Dean Russell KAHN ,  Ellen Ruth LAIRD ,  Andrew Terrance METCALF ,  David Austin MORENO ,  Bradley Jon NEWHOUSE ,  Spencer Phillip PAJK ,  Brett Joseph PRIGARO ,  Li REN ,  Eugene TARLTON

IPC: C07D403/12 ,  C07D239/90 ,  C07D239/91

Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

公开(公告)号：US20220251083A1

公开(公告)日：2022-08-11

申请号：US17720070

申请日：2022-04-13

Applicant: Array BioPharma Inc.

Inventor： James Francis BLAKE ,  Mark Laurence BOYS ,  Mark Joseph CHICARELLI ,  Adam Wade COOK ,  Mohamed S. A. ELSAYED ,  Jay Bradford FELL ,  John P. FISCHER ,  Ronald Jay HINKLIN ,  Yutong JIANG ,  Oren Teague MCNULTY ,  Macedonio J. MEJIA ,  Martha E. RODRIGUEZ ,  Christina Elizabeth WONG

IPC: C07D471/04 ,  A61P35/00 ,  C07D401/14 ,  C07D471/10 ,  C07D513/10

Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：US20220112214A1

公开(公告)日：2022-04-14

申请号：US17274990

申请日：2019-09-06

Applicant: ARRAY BIOPHARMA INC.

Inventor： James F. BLAKE ,  Donghua DAI ,  Julia HAAS ,  Yutong JIANG ,  Dean KAHN ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Andrew T. METCALF ,  David A. MORENO ,  Brett PRIGARO ,  Ginelle A. RAMANN ,  Li REN ,  Shane M. WALLS ,  Hailong ZHANG

IPC: C07D498/22 ,  C07D513/22 ,  C07D498/14 ,  A61K45/06 ,  A61K31/554 ,  A61K31/55 ,  A61K31/519 ,  C07D487/14 ,  A61P35/00

Abstract: Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US11267818B2

公开(公告)日：2022-03-08

申请号：US17020461

申请日：2020-09-14

Applicant: Array BioPharma Inc.

Inventor： Julia Haas ,  Steven W. Andrews ,  Yutong Jiang ,  Gan Zhang

IPC: C07D487/04 ,  C07D471/04 ,  C07D519/00 ,  A61P29/00 ,  A61K9/00 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06

Abstract: Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.

公开(公告)号：US11104676B2

公开(公告)日：2021-08-31

申请号：US16555432

申请日：2019-08-29

Applicant: Array BioPharma Inc.

Inventor： Ronald Jay Hinklin ,  Shelley Allen ,  Patrick Barbour ,  Adam Cook ,  Joshua Dahlke ,  John Gaudino ,  Ellen Laird ,  Oren T. McNulty ,  Qian Zhao

IPC: C07D471/04

Abstract: Provided herein are compounds of the Formula I: and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.

公开(公告)号：US11098064B2

公开(公告)日：2021-08-24

申请号：US16902424

申请日：2020-06-16

Applicant: Loxo Oncology, Inc. ,  Array BioPharma Inc.

Inventor： Charles Todd Eary ,  Stacey Spencer ,  Zack Crane ,  Katelyn Chando ,  Sylvie Asselin ,  Weidong Liu ,  Mike Welch ,  Adam Cook ,  Gabrielle R. Kolakowski ,  Andrew T. Metcalf ,  David A. Moreno ,  Tony P. Tang

IPC: C07D519/00 ,  C07D471/04

Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.